Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 18, 2026, 2:00 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 169–192 of 2,241 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: RNA sequencing Clear all
Terminated Not applicable Interventional Accepts healthy volunteers

Effects of a Complex, Partnered Martial Arts-based Intervention on Cognitive Function

NCT04760054
View directory record Official record
Conditions
Cognitive Change, Processing, Visual Spatial, Inhibition (Psychology), Working Memory
Interventions
HUBOD, Active Comparator, Control Condition
Behavioral
Lead sponsor
University of Illinois at Urbana-Champaign
Other
Eligibility
18 Years to 45 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Urbana, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 25, 2022 · Synced Oct 18, 2026, 2:00 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Teen Health Choices & Wellness

NCT06822569
View directory record Official record
Conditions
Health Behavior, Wellness, Psychological, Substance Use
Interventions
Cue reactivity paradigm
Other
Lead sponsor
Brown University
Other
Eligibility
13 Years to 16 Years
Enrollment
224 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2028
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Sep 29, 2026 · Synced Oct 18, 2026, 2:00 AM EDT
Completed Phase 4 Interventional Results available

Comparison of the Effect of Exenatide Versus Sitagliptin on 24-hour Average Glucose in Patients With Type 2 Diabetes on Metformin or a Thiazolidinedione

NCT00729326
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
exenatide, sitagliptin, placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 70 Years
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Apr 9, 2015 · Synced Oct 18, 2026, 2:00 AM EDT
Completed Phase 1 Interventional

An Open-label, Phase 1 Study to Determine the Maximum Tolerated Dose of HLX07,in Patients With Advanced Solid Cancers

NCT02648490
View directory record Official record
Conditions
Solid Tumour
Interventions
HLX07, Acetaminophen, dexamethasone, diphenhydramine, 5-HT3 inhibitor
Drug
Lead sponsor
Henlix, Inc
Industry
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Fremont, California
Source: ClinicalTrials.gov public record
Updated Jul 30, 2019 · Synced Oct 18, 2026, 2:00 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

To Evaluate the Cardiac Safety and PK Following a Single Oral Dose Administration of Pacritinib in Healthy Subjects

NCT02807207
View directory record Official record
Conditions
Healthy Subjects
Interventions
A: pacritinib, B: Placebo, C: moxifloxacin
Drug · Other
Lead sponsor
CTI BioPharma
Industry
Eligibility
18 Years to 55 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Evansville, Indiana
Source: ClinicalTrials.gov public record
Updated Sep 15, 2023 · Synced Oct 18, 2026, 2:00 AM EDT
Completed Phase 1 Interventional

An Open-Label Study of Aripiprazole Lauroxil in Subjects With Stable Schizophrenia

NCT02320032
View directory record Official record
Conditions
Schizophrenia
Interventions
Aripiprazole Lauroxil
Drug
Lead sponsor
Alkermes, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
16
States / cities
Little Rock, Arkansas • Cerritos, California • Garden Grove, California + 13 more
Source: ClinicalTrials.gov public record
Updated Aug 29, 2018 · Synced Oct 18, 2026, 2:00 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Motivational Refinements for Facilitating Reinforcement Schedule Thinning

NCT05790668
View directory record Official record
Conditions
Decreasing Destructive Behavior, Increasing Functional Communicative Behavior
Interventions
Traditional Schedule Thinning, PIA-Informed Schedule Thinning, PIA-Informed Schedule Thinning with Competing Stimuli
Behavioral
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
3 Years to 17 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2028
U.S. locations
2
States / cities
New Brunswick, New Jersey • Somerset, New Jersey
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Oct 18, 2026, 2:00 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Assess the Food Effect of K-877 in Healthy Adult Volunteers

NCT04742218
View directory record Official record
Conditions
Healthy
Interventions
K-877
Drug
Lead sponsor
Kowa Research Institute, Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Aug 9, 2021 · Synced Oct 18, 2026, 2:00 AM EDT
Completed Phase 2 Interventional

Safety and Efficacy of the Therapeutic Vaccine GI-4000 in Combination With Gemcitabine Versus Placebo for the Treatment of Non-metastatic, Post-resection Pancreas Cancer

NCT00300950
View directory record Official record
Conditions
Pancreas Cancer
Interventions
GI-4000, Gemcitabine
Biological · Drug
Lead sponsor
GlobeImmune
Industry
Eligibility
18 Years and older
Enrollment
176 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2015
U.S. locations
18
States / cities
Birmingham, Alabama • Beverly Hills, California • La Jolla, California + 14 more
Source: ClinicalTrials.gov public record
Updated Apr 6, 2015 · Synced Oct 18, 2026, 2:00 AM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Epigenetic Regulation of Human Adipose Tissue Distribution

NCT02728635
View directory record Official record
Conditions
Obesity
Interventions
Dual-energy X-ray absorptiometry (DEXA)/ Magnetic resonance imaging (MRI) and Magnetic resonance spectroscopy (MRS), Adipose tissue biopsies, FSIGTT/ RMR
Other · Procedure
Lead sponsor
AdventHealth Translational Research Institute
Other
Eligibility
18 Years to 45 Years
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2026
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Mar 27, 2026 · Synced Oct 18, 2026, 2:00 AM EDT
Completed Not applicable Interventional Results available

Vidatalk Communication Application: Usability, Acceptability and Efficacy Study

NCT02921776
View directory record Official record
Conditions
Nonverbal Communication, Critical Illness
Interventions
Aim 1 - VidaTalk - post-extubation, Aim 2 - VidaTalk - intubated, Aim 3 - VidaTalk tablet app, Aim 3 - attention-control with non-VidaTalk tablet
Other · Device
Lead sponsor
Ohio State University
Other
Eligibility
18 Years to 99 Years
Enrollment
147 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 31, 2022 · Synced Oct 18, 2026, 2:00 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetic Interaction of Darapladib and CYP 3A4 in Healthy Subjects

NCT01873339
View directory record Official record
Conditions
Atherosclerosis
Interventions
Darapladib, Midazolam
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 65 Years
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 15, 2017 · Synced Oct 18, 2026, 2:00 AM EDT
Completed Phase 2 Interventional Results available

A Phase 2, Pharmacokinetic (PK) Study of 6R-BH4 Alone or 6R-BH4 With Vitamin C in Subjects With Endothelial Dysfunction

NCT00532844
View directory record Official record
Conditions
Endothelial Dysfunction
Interventions
Sapropterin Dihydrochloride, Sapropterin Dihydrochloride and Vitamin C
Drug
Lead sponsor
BioMarin Pharmaceutical
Industry
Eligibility
18 Years to 75 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Hackensack, New Jersey
Source: ClinicalTrials.gov public record
Updated May 17, 2021 · Synced Oct 18, 2026, 2:00 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Traveling-wave Transcranial Electric Stimulation

NCT05399381
View directory record Official record
Conditions
Working Memory
Interventions
Transcranial alternating current stimulation (tACS)
Device
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 45 Years
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Oct 18, 2026, 2:00 AM EDT
Active, not recruiting Phase 2 Interventional

Two-period Crossover Study to Demonstrate the Comparability of Pharmacokinetics of Subcutaneous Ianalumab Between 2mL Auto-injector/2mL PFS with1mL Pre-filled Syringe in Adult Participants With Autoimmune Disease

NCT06293365
View directory record Official record
Conditions
Sjögrens Disease, Systemic Lupus Erythematosus, Rheumatoid Arthritis
Interventions
VAY736 1ml PFS, VAY736 2 ml PFS, VAY736 2ml AI
Biological
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 70 Years
Enrollment
155 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
17
States / cities
Anniston, Alabama • Fullerton, California • La Palma, California + 14 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2026 · Synced Oct 18, 2026, 2:00 AM EDT
Enrolling by invitation No phase listed Observational Accepts healthy volunteers

Truway Whole-Body Digital Twin and Physiologic Resilience Study (TRU-OMNIBODY)

NCT07805044
View directory record Official record
Conditions
PHYSIOLOGICAL PHENOMENA, Homeostasis, Physical Functional Performance, Cardiorespiratory Fitness, Cardiometabolic Risk Factors, Mobility Limitation
Interventions
Standardized Physiologic Resilience Challenge, Multimodal Whole-Body Physiologic Monitoring, Research-Only Whole-Body Digital Twin Analysis
Procedure · Other
Lead sponsor
Truway Health, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
450 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2041
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 4, 2026 · Synced Oct 18, 2026, 2:00 AM EDT
Completed No phase listed Observational Results available

Feasibility - Infinitome

NCT04563767
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Infinitome
Procedure
Lead sponsor
HealthPartners Institute
Other
Eligibility
40 Years to 90 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 17, 2021 · Synced Oct 18, 2026, 2:00 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

A Study to Assess the Synergistic Effects of a Cranberry Beverage on Cognitive Function

NCT05008549
View directory record Official record
Conditions
Attention, Mood
Interventions
Cranberry Juice Product
Dietary Supplement
Lead sponsor
Ocean Spray Cranberries, Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 7, 2023 · Synced Oct 18, 2026, 2:00 AM EDT
Active, not recruiting Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetics of Zelquistinel in Fasted or Fed State

NCT07099989
View directory record Official record
Conditions
Healthy Volunteers in Fed and Fasted State
Interventions
Zelquistinel 3 mg, Zelquistinel 10 mg
Drug
Lead sponsor
Syndeio Biosciences, Inc
Industry
Eligibility
18 Years to 59 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Mar 20, 2026 · Synced Oct 18, 2026, 2:00 AM EDT
Completed Not applicable Interventional Results available

Improving Adherence to Oral Antipsychotic Medications in People With Schizophrenia

NCT00406718
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
Med-eMonitor, PharmCAT, Treatment as Usual
Behavioral
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years to 60 Years
Enrollment
197 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2013
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Oct 5, 2015 · Synced Oct 18, 2026, 2:00 AM EDT
Completed Not applicable Interventional Results available

Prospective Elimination Of Distal Coronary Sinus-Left Atrial Connections for Atrial Fibrillation Ablation Trial

NCT03646643
View directory record Official record
Conditions
Atrial Fibrillation, Arrhythmias, Cardiac
Interventions
Standard Atrial fibrillation ablation, Coronary sinus to left atrium connection elimination
Procedure
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 29, 2024 · Synced Oct 18, 2026, 2:00 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Effect of Antacid on Bioavailability of Febuxostat After Administration of a Febuxostat 80 mg Extended-Release Capsule

NCT02382640
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Febuxostat XR, Maalox Advance Regular Strength liquid
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 55 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Apr 29, 2016 · Synced Oct 18, 2026, 2:00 AM EDT
Completed Phase 3 Interventional

Optimizing Pharmacologic Treatment for Neonatal Opioid Withdrawal Syndrome (OPTimize NOW): A Symptom-Based Dosing Approach

NCT05980260
View directory record Official record
Conditions
Neonatal Opiate Withdrawal Syndrome
Interventions
Symptom-based Dosing Approach, Scheduled Opioid Taper Approach
Other
Lead sponsor
HELP for NOWS Consortium
Network
Eligibility
1 Hour to 48 Hours
Enrollment
626 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
23
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Wilmington, Delaware + 16 more
Source: ClinicalTrials.gov public record
Updated May 18, 2026 · Synced Oct 18, 2026, 2:00 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Effect of Rifampin (RIF) on the Pharmacokinetics (PK) of Oral Cabotegravir (CAB) in Healthy Subjects

NCT02411435
View directory record Official record
Conditions
Infection, Human Immunodeficiency Virus
Interventions
CAB, RIF
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 65 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Jan 6, 2016 · Synced Oct 18, 2026, 2:00 AM EDT